Alveolar Macrophage Deactivation in Murine Septic Peritonitis: Role of Interleukin 10
Open Access
- 1 March 2001
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (3), 1394-1401
- https://doi.org/10.1128/iai.69.3.1394-1401.2001
Abstract
Sepsis predisposes the host to a number of infectious sequelae, particularly the development of nosocomial pneumonia. Mechanisms by which sepsis results in impairment of lung antibacterial host defense have not been well defined. Alveolar macrophages (AM) represent important immune effector cells of the lung airspace. In this study, we examined the effects of cecal ligation and puncture (CLP) on murine AM function ex vivo, including the expression of proinflammatory cytokines and AM phagocytic activity. AM were harvested from mice subjected to a sham operation and CLP 24 h after laparotomy, adherence purified, and challenged with lipopolysaccharide (LPS) or left unstimulated. Both unstimulated and LPS-stimulated AM from mice subjected to CLP (CLP mice) produced significantly smaller amounts of proinflammatory cytokines tumor necrosis factor alpha and interleukin (IL-12) and C-X-C chemokines KC and macrophage inflammatory protein 2 than similarly treated AM from animals subjected to a sham operation. Furthermore, AM isolated from CLP mice displayed a marked impairment in phagocytic activity, as determined by flow cytometry, with this defect persisting to 48 h post-CLP. Induction of peritoneal sepsis syndrome resulted in a time-dependent increase in IL-10 in plasma and peritoneal fluid. Interestingly, the impairment in AM proinflammatory-cytokine production and phagocytic activity observed in AM from CLP mice was partially reversed by the in vivo neutralization of IL-10 prior to AM harvest. These observations suggest that abdominal sepsis syndrome results in significant impairment in AM effector cell function, which is mediated, in part, by sepsis-induced expression of IL-10.Keywords
This publication has 42 references indexed in Scilit:
- Antiinflammatory Cytokine Responses during Clinical Sepsis and Experimental Endotoxemia: Sequential Measurements of Plasma Soluble Interleukin (IL)-1 Receptor Type II, IL-10, and IL-13The Journal of Infectious Diseases, 1997
- Monocyte deactivation-rationale for a new therapeutic strategy in sepsisIntensive Care Medicine, 1996
- Interleukin-10 inhibits neutrophil phagocytic and bactericidal activityFEMS Immunology & Medical Microbiology, 1996
- Interleukin (IL)-10 Inhibits Nuclear Factor кB (NFкB) Activation in Human MonocytesJournal of Biological Chemistry, 1995
- Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2.The Journal of Experimental Medicine, 1994
- Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation.The Journal of Experimental Medicine, 1994
- Interleukin‐10 controls interferon‐γ and tumor necrosis factor production during experimental endotoxemiaEuropean Journal of Immunology, 1994
- Interleukin-10Annual Review of Immunology, 1993
- Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.The Journal of Experimental Medicine, 1993
- Immunomodulatory Therapy With Thymopentin and IndomethacinAnnals of Surgery, 1991